My earlier article presented the worrisome research integrity record at the gigantic US cancer research hospital MD Anderson Cancer Center, part of the University of Texas in Houston. Its particular focus was the ovarian cancer researcher Anil Sood, professor of Gynecologic Oncology and Reproductive Medicine and co-director of Center for RNA Interference and Non-Coding RNAs at MD Anderson. Meanwhile I have been contacted by no less than 4 former Sood associates with their concerns, because they say MD Anderson does not take them seriously. A pseudonymous guest post by one of these whistleblowers, together with some evidence, is published below.
Sood’s record of appalling duplications of microscopy image and western blot bands in his papers is evident on PubPeer, no less than 40 papers are flagged, spanning so far a period from 2004 until now. The whistleblowers who contacted me now also accuse Sood of inappropriate data handling, since he was apparently removing or adjusting data points on a whim, and taught his lab members to do the same. The results based on this creatively acquired mouse experiment data as well as duplicated images served to initiate at MD Anderson a clinical trial with up to 90 “patients with histologic proof of advanced solid tumors ” to test a siRNA based therapy, this trial is lead by Sood’s associate Robert Coleman, who is professor at the same department.
Worst of all: MD Anderson doesn’t care about what happens in Sood’s lab. They do have guidelines for research integrity, printable as pdf, but those seem to serve as a kind of toilet paper to wipe professorial bums with. As a whistleblower informed me, nine researchers working on different projects in Sood’s lab complained to Office of Research Integrity (ORI) or MD Anderson’s own Research Integrity Officer (RIO) William Plunkett or Department Chairs or Ombuds Office or Dean of Graduate School, Michelle Barton, since August 2016. In fact, those who complained where told to find another job, or were dealt otherwise with. There never was any investigation, only “leak of confidentiality”, while the University of Texas graduate school keeps sending fresh students to learn at Sood’s lab. Meanwhile, as a whistleblower wrote: “Most Sood core members already escaped, and got a job thanks to their publication with suspected allegations“.
Continue reading “Anil Sood and how much MD Anderson doesn’t care: whistleblowers speak out”
Recent news brought us yet another retraction of the Spanish zombie scientist Susana Gonzalez, formerly famous for her impactful ERC-funded research into stem cells and ageing. It is her fifth retraction (others here), and meanwhile Gonzalez is not even a zombie scientist anymore. She has no research group in her new Madrid institute, noone in Spain wants to work in the same building with her, in fact though she is still formally employed with the Spanish Consejo Superior de Investigaciones Científicas (CSIC), it seems she stopped coming to work long ago, being on an endless sick leave. Even the European Research Council (ERC), usually most accommodating with research misconduct of their elite grant recipients, didn’t know what to do with Gonzalez suspended €2Mn grant and eventually terminated it.
The recent Gonzalez retraction at the Molecular and Cellular Biology (MCB) is interesting in two aspects. First, Retraction Watch previously chastised the journal in a headline for allegedly refusing to investigate evidence of data manipulations in papers older than 6 years (read here). No reference is made to that “smear” accusation in the current Retraction Watch article on Gonzalez retraction. But the second aspect is really much more intriguing. The retracted MCB paper, from Gonzalez period as postdoc at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, was coauthored by the US researcher Carol Prives, professor at the Columbia University in New York, and specialist for the cell cycle control protein p53: Continue reading “Carol Prives, innocent victim of Susana Gonzalez’ data manipulations?”
The MD Anderson Cancer Center, part of the University of Texas and located in Houston, is a giant hub of huge cancer research money, even for US standards. They also do a lot of science there, which only purpose seems to be publishing in big journals in order to generate even more money. If there is any genuine interest to help cancer patients with actual research: this stands in a stark contrast with MD Anderson’s evident attitude to research reproducibility and data integrity. A number of their star researchers who published in most respectable journals papers, had their data flagged on the whistleblowing platform PubPeer as highly problematic. Yet MD Anderson apparently cannot care less. Their star cancer researcher and businessman Raghu Kalluri was never investigated for many problems in his publications, either in those with or those without his misconduct-tainted Portuguese co-author and ex-MD Anderson employee Sonia Melo. When nobody ever investigates your research practices (e.g., because your research institution is blinded by the investor money you brought in), you will per definition never be found guilty of any misconduct. This is probably exactly why the elite journal Nature recently accepted a new paper from the Kalluri lab (Kamerkar et al 2017), on the same topic of exosomes as cancer biomarkers as his irreproducible earlier masterpiece with Melo (Melo et al, Nature 2015). The new Nature paper even again features the same disgraced co-author, who lost a Nature Genetics paper (Melo et al, 2009) and her EMBO Young Investigator funding due to data manipulation.
There is more evidence for research misconduct at MD Anderson. Continue reading “Anil Sood and other questionable stars of MD Anderson”
On June 9th 2017, the research integrity news website Retraction Watch brought an article titled: „Journal won’t look at allegations about papers more than six years old, nor from “public websites””. A public outcry followed, protesting about what was perceived an outrageous case of editorial cover-up of research fraud. The journal in question was Molecular & Cellular Biology (MCB), published by the American Society for Microbiology (ASM); the vituperative Retraction Watch article was prompted by an editorial in the June issue of this journal. The problem with that name-and-shame Retraction Watch article however was: the accusatory title did not fit their own main text at all, which did actually clarify that evidence on public websites like PubPeer is in fact very much looked at by the MCB journal editors, just not publicly commented upon. And that:
“The ASM spokesperson explained that, like the ORI, ASM journals will make exceptions to the six-year statute of limitations, for instance if older papers “provide evidence of an extensive pattern of misconduct.””
Continue reading “Journal announces to clean up past literature, gets “smeared” by Retraction Watch”
This article lists all known (including those not officially declared) patients of the scandal surgeon Paolo Macchiarini, who received from him a cadaveric or plastic trachea. All these grafts were “regenerated” with bone marrow and epithelial cells, in some cases a bioreactor was used to incubate cells on the trachea carcass, in some cases a “bionic” method was applied, where cells were brought straight into the open patient, together with growth factors like EPO. Not all patients are named in my list, though names of all are available, certainly at the hospitals where they were treated. One of my sources is a patients list from the Careggi Hospital in Florence, Italy, which the Corriere Fiorentino journalist Alessio Gaggioli sent me. Some of the patients I already described in an earlier article.
This now is a full list, and it will be updated whenever I receive any new evidence. All Macchiarini trachea transplant patients are listed in the chronological order of their operation. The 2003 operated patient (story here), who received from Macchiarini (together with Heike and Thorsten Walles) a small “regenerated” tracheal patch of pig intestine, is not included here, as it was not a trachea transplant as such. There is a total of 17 patients, at least 11 are dead, the rest, if alive, were left mutilated.
Continue reading “Macchiarini’s trachea transplant patients: the full list”
Sonia Melo, the Portuguese cheater scientist and her former US-boss Raghu Kalluri issued some days ago a biorxive preprint, which sole purpose is to defend their discredited Nature paper from 2015. There, they originally claimed to have found a unique biomarker for early pancreatic cancer, a much hailed promise to save lives of many cancer patients. However, soon it was found out that the results were not reproducible, the Nature paper Melo et al, 2015 contained evidence of data manipulation (just like other Melo publications with Kalluri and her PhD boss Manel Esteller). The antibody, on which the central evidence for the allegedly unique pancreatic cancer biomarker glypican 1 (GPC1) was based, proved to be delivering staining artefacts; the vendor Thermo Scientific soon discontinued it. Even Kalluri seemingly distanced himself from his results.
Now in their new preprint, Melo and Kalluri claimed to have perfectly reproduced their original 2015 GPC1 results with a new antibody, which however proved to be likely exactly the same as the old one, but sold by a different vendor. As soon as this became known, the authors issued a new preprint version just two days later, featuring yet another entirely new GPC1 antibody, with an utterly new set of results to complement the 6 day older ones. However, also these results are most likely useless. The authors namely freely admit in their preprint method description to have intentionally manipulated their flow cytometry (FACS) data to obtain a positive signal specifically where needed. It seems that one full professor and three research group leaders have absolutely no understanding about data integrity in flow cytometry (or maybe even in research in general). Obviously, they simply adjust the FACS settings for each sample in an analytic row any way it pleases them until they see a result they like. As they don’t even hide it, they seem to think this is the proper way to do science. Continue reading “Melo and Kalluri defend discredited Nature paper with preprint, where they admit data “adjustments””
The pharma giant Pfizer announced to continue investigating the data manipulations committed by their former cancer researcher Min-Jean Yin, retractions of two more publications were requested and yet another paper’s fate is being currently decided. Again it is about studies of pharmacological inhibitors of cancer molecular pathways which Yin’s former lab at the Pfizer California research site has faked. These two retraction requests come is addition to 5 Yin retractions which Pfizer already announced on my site in October 2016 and which meanwhile happened. The PubPeer-listed evidence was first presented on my site in May 2016. Back then, the reader of my site, who posted that evidence of duplicated western blots on PubPeer and alerted me to it, preferred to remain unnamed. Now however, she agreed to be named: it was the microbiologist, image integrity specialist and host of the successful public outreach blog Microbiome Digest, Elisabeth Bik. She now forwarded to me this message: Continue reading “Pfizer announces more retractions for sacked lab head Min-Jean Yin, whistleblower revealed”